The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

NEW YORK – Cizzle Biotechnology said on Tuesday it has raised £150,000 ($200,635) to support the rollout of its lung cancer early detection test in the UK and other European countries.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Healthcare Royalty Partners purchased anticipated royalties and milestone payments, and Regenxbio received $150 upfront at closing.